Abstract:Purpose:The T-cell-inflamed phenotype correlates with efficacy of immune-checkpoint blockade, whereas non-T-cell-inflamed tumors infrequently benefit. Tumor-intrinsic WNT/β-catenin signaling mediates immune exclusion in melanoma, but association with the non-T-cell-inflamed tumor microenvironment in other tumor types is not well understood.Experimental Design:Using The Cancer Genome Atlas (TCGA), a T-cell-inflamed gene expression signature segregated samples within tumor types. Activation of WNT/β-catenin signaling was inferred using three approaches: somatic mutations or somatic copy number alterations (SCNA) in β-catenin signaling elements including CTNNB1, APC, APC2, AXIN1, and AXIN2; pathway prediction from RNA-sequencing gene expression; and inverse correlation of β-catenin protein levels with the T-cell-inflamed gene expression signature.Results:Across TCGA, 3,137/9,244 (33.9%) tumors were non-T-cell-inflamed, whereas 3,161/9,244 (34.2%) were T-cell-inflamed. Non-T-cell-inflamed tumors demonstrated significantly lower expression of T-cell inflammation genes relative to matched normal tissue, arguing for loss of a natural immune phenotype. Mutations of β-catenin signaling molecules in non-T-cell-inflamed tumors were enriched three-fold relative to T-cell-inflamed tumors. Across 31 tumors, 28 (90%) demonstrated activated β-catenin signaling in the non-T-cell-inflamed subset by at least one method. This included target molecule expression from somatic mutations and/or SCNAs of β-catenin signaling elements (19 tumors, 61%), pathway analysis (14 tumors, 45%), and increased β-catenin protein levels (20 tumors, 65%).Conclusions:Activation of tumor-intrinsic WNT/β-catenin signaling is enriched in non-T-cell-inflamed tumors. These data provide a strong rationale for development of pharmacologic inhibitors of this pathway with the aim of restoring immune cell infiltration and augmenting immunotherapy.See related commentary by Dangaj et al., p. 2943

The oncogenic activation of β-catenin

Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC

Mechanisms of Cytoplasmic β-Catenin Accumulation and Its Involvement in Tumorigenic Activities Mediated by Oncogenic Splicing Variant of the Receptor Originated from Nantes Tyrosine Kinase

Wnt-independent Beta-Catenin Transactivation in Tumor Development.

Phosphorylation of β-Catenin by AKT Promotes β-Catenin Transcriptional Activity

Wnt/β-catenin Singal Transduction Pathway and Colorectal Cancer

Phosphorylation Of Beta-Catenin By Akt Promotes Beta-Catenin Transcriptional Activity

Transcriptional Regulation of Wnt/β-Catenin Pathway in Colorectal Cancer

Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation

APC controls Wnt-induced β-catenin destruction complex recruitment in human colonocytes

Polycomb Protein Ezh2 Activates Wnt/Beta-Catenin Signaling To Promote Hepatocellular Carcinoma Development

The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes

Regulation of the phosphorylation and nuclear import and export of β-catenin by APC and its cancer-related truncated form.

Β-Catenin/tcf4 Complex Induces the Epithelial-to-mesenchymal Transition (Emt)-Activator ZEB1 to Regulate Tumor Invasiveness.

Aberrant Wnt/β-Catenin Signaling in Pancreatic Adenocarcinoma

Beta- and Gamma-Catenin Mutations, but Not E-cadherin Inactivation, Underlie T-cell Factor/lymphoid Enhancer Factor Transcriptional Deregulation in Gastric and Pancreatic Cancer.

Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma.

APC Mutations Disrupt Β-Catenin Destruction Complex Condensates Organized by Axin Phase Separation

The regulation of β-catenin activity and function in cancer: therapeutic opportunities

WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers